Hutch News

Hutch News

Stories tagged 'CAR t-cell'

Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy

Immune-based treatments move from the fringes to the spotlight

June 16, 2017 | By Susan Keown / Fred Hutch News Service

What's new in cancer immunotherapy? Five hot topics, from new combination therapies to cost.

View story >


Dissolving implant could bring immunotherapy to solid tumors

A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study

April 24, 2017 | By Sabrina Richards / Fred Hutch News Service

A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.

View story >


Fred Hutch opens first-of-its kind Bezos Family Immunotherapy Clinic

Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies

Nov. 1, 2016 | By Fred Hutch News Service

The new clinic will allow researchers to conduct twice as many immunotherapy trials and enable intensive patient monitoring to improve experimental therapies.

View story >


Replenishing immune cells after remission

New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy

Oct. 17, 2016 | By Bill Briggs / Fred Hutch News Service

Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Oct. 13, 2016

Dr. David Maloney named cellular immunotherapy medical director at Fred Hutch, SCCA; Dr. Jim Kublin gets grant to study how gut bugs alter HIV vaccine response.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.